What is the half-life of KPV?
The published plasma half-life of KPV is short — typical of tripeptides without engineered long-acting modifications — but the compound’s intestinal-epithelial-cell uptake via PepT1 and downstream anti-inflammatory effects persist beyond the plasma-clearance window.
What the research literature says
KPV is a 3-amino-acid tripeptide (Lys-Pro-Val) without engineered modifications to extend the in-vivo half-life. The plasma pharmacokinetics reflect the short circulating residence typical of small unmodified peptides — clearance within hours of administration. The functional pharmacology operates on a longer time scale through the PepT1-mediated cellular uptake and downstream transcriptional effects.
The Dalmasso work on PepT1-mediated KPV uptake (PMID 18061177) established the cellular-pharmacology framework. The compound is selectively taken up by intestinal epithelial cells expressing the PepT1 proton-coupled peptide transporter, with the uptake step concentrating the compound at the site of action — the intestinal mucosa — independent of systemic plasma concentrations. The Kannengiesser anti-inflammatory work in murine IBD models documented the functional response time scale (PMID 18092346).
The Viennois colitis-associated cancer work documented PepT1’s critical role in the KPV pharmacology framework (PMID 27458604). The Xiao orally-targeted delivery work characterised hyaluronic-acid-functionalised nanoparticle delivery as a strategy to maximise PepT1-mediated uptake (PMID 28143741). Across these studies, dosing intervals are set to the functional response time scale rather than the plasma-clearance window.
Why this matters in research context
KPV’s pharmacology is concentrated at the intestinal mucosa via PepT1-mediated uptake — the plasma half-life is less relevant to functional effects than for systemically-acting compounds. Researchers using KPV should anchor protocol design to the GI-inflammation framework where the compound’s documented effects are operative, rather than treating it as a systemic anti-inflammatory tool.
Related compounds
- KPV 10mg — the compound covered by this answer
- KLOW Blend — four-compound formulation including KPV
Related research questions
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-178. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14(3):324-331. [PMID 18092346]
- Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016;2(3):340-357. [PMID 27458604]
- Xiao B et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther 2017;25(7):1628-1640. [PMID 28143741]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. KPV is sold strictly as a research-grade reagent for laboratory and bench research applications.